Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc.

Overview
Date Founded

2012

Headquarters

611 Gateway Boulevard, Suite 900, South San Francisco, CA, 94080, USA

Type of Company

Public

Employees (Worldwide)

311

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals

Company Description

Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at Atara Biotherapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Senior Vice President & Chief Financial Officer

Secretary, Senior Vice President & General Counsel

Executive Vice President, Research & Development & Chief Scientific Officer

Senior Vice President, Chief Medical Officer

Senior Vice President, Head of GMP Quality & Process Sciences

Executive Vice President, Chief Technical Operations Officer

Senior Vice President & Global Commercial Head

Senior Vice President, Global Human Resources

Senior Vice President, Global Medical Affairs Head

Board of Directors

Senior Advisor, Finance at Crinetics Pharmaceuticals, Inc.

Chief Medical Officer at Merck & Co., Inc.

President & Chief Executive Officer at AMAG Pharmaceuticals, Inc.

Managing Director at Westlake Village BioPartners

Executive Chair at Atara Biotherapeutics, Inc.

Former Chief Operating Officer at Seattle Genetics, Inc.

President & Chief Executive Officer at Atara Biotherapeutics, Inc.

Paths to Atara Biotherapeutics, Inc.
Potential Connections via
Relationship Science
You
Atara Biotherapeutics, Inc.
Owners & Shareholders
Details Hidden

The Baupost Group employs a value-oriented, multi-strategy investment approach that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seek to invest in assets which are undervalued relative to their market price. The Baupost Group invest, either directly or indirectly, in securities and other assets that have some or all of the following characteristics: (1) they are currently out-of-favor, but have good prospects (2) they sell at a significant discount to underlying economic value (3) they have catalysts in place for the realization of underlying value (4) they are highly complex (5) they are somewhat or highly illiquid and (6) they sell at prices below what would reasonably be expected due to market imperfections and inefficiencies, including but not limited to temporary supply demand imbalances, information gaps, and selling pressures. They invest across a range of financial instruments, asset classes and geographic regions. Investments may include securities and assets of all types, including, but not limited to, stock (common, preferred and convertible), warrants, options, swaps, trade claims, bank debt, bonds, other debt instruments including self-originated loans, currency, futures, derivatives, commodities, contract rights, royalty interests, non-US securities and other assets (including in emerging markets), structured investment vehicles, secured and unsecured instruments, ABS, CMBS, RMBS, real estate and related instruments, other complex financial instruments and rights and distressed assets. Securities may be listed or traded on domestic or non-US exchanges or other trading networks (including OTC markets), as well as securities that are unlisted and trade infrequently or not at all.

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Camber Capital Management seeks to generate capital appreciation without regard to current income. They seek to achieve this objective by investing primarily in publicly-traded common stocks of healthcare companies across a variety of industries including healthcare services and facilities, pharmaceuticals, medical products and devices and biotechnology. Although most of their investments are within the healthcare industry, Camber may occasionally invest in other sectors if more attractive opportunities are identified.Camber employs a fundamental, bottom-up research approach designed to identify high-quality companies whose inherent value is not adequately reflected in a company's market valuation. The firm believes that the excessive focus on short-term returns and near term catalysts within the healthcare space often causes public market prices to greatly overreact to near term news flow. Camber takes on short-term risk in order to capitalize on attractive intermediate- to long-term opportunities. To maximize returns, they may, on occasion, employ the use of leverage.

Recent Transactions
Details Hidden

Atara Biotherapeutics, Inc. issued . USD Common Stock

Details Hidden

Atara Biotherapeutics, Inc. issued USD Common Stock

Details Hidden

Atara Biotherapeutics, Inc. issued Common Stock

Transaction Advisors
Escrow Agent

Advised onAtara Biotherapeutics, Inc. issued USD Common Stock

Auditor

Advised onAtara Biotherapeutics, Inc. issued USD Common Stock

Underwriter

Advised onAtara Biotherapeutics, Inc. issued Common Stock

Legal Advisor

Advised onAtara Biotherapeutics, Inc. issued USD Common Stock

Underwriter

Advised onAtara Biotherapeutics, Inc. issued USD Common Stock

Managing Director, Health Care Investment Banking Group

Advised onAtara Biotherapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Cooley LLP

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Legal Advisor

Partner at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP

Key Stats and Financials As of 2018
Market Capitalization
$723M
Total Enterprise Value
$1.21B
Earnings Per Share
$-5.27
Revenue
$0
Total Equity
$339M
Net Profit
$-231M
TEVNet Income
-5.26x
Debt TEV
0x
Total Debt
$600K
EBITDA
$-233M
Investors
Details Hidden

The Baupost Group employs a value-oriented, multi-strategy investment approach that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seek to invest in assets which are undervalued relative to their market price. The Baupost Group invest, either directly or indirectly, in securities and other assets that have some or all of the following characteristics: (1) they are currently out-of-favor, but have good prospects (2) they sell at a significant discount to underlying economic value (3) they have catalysts in place for the realization of underlying value (4) they are highly complex (5) they are somewhat or highly illiquid and (6) they sell at prices below what would reasonably be expected due to market imperfections and inefficiencies, including but not limited to temporary supply demand imbalances, information gaps, and selling pressures. They invest across a range of financial instruments, asset classes and geographic regions. Investments may include securities and assets of all types, including, but not limited to, stock (common, preferred and convertible), warrants, options, swaps, trade claims, bank debt, bonds, other debt instruments including self-originated loans, currency, futures, derivatives, commodities, contract rights, royalty interests, non-US securities and other assets (including in emerging markets), structured investment vehicles, secured and unsecured instruments, ABS, CMBS, RMBS, real estate and related instruments, other complex financial instruments and rights and distressed assets. Securities may be listed or traded on domestic or non-US exchanges or other trading networks (including OTC markets), as well as securities that are unlisted and trade infrequently or not at all.

Details Hidden

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Details Hidden

Domain Associates invests exclusively in emerging life sciences companies. The firm focuses on pharmaceuticals, specialty pharmaceuticals and medical devices and they are also interested in biomaterials, bioinstrumentation and diagnostics. They prefer to be part of the first institutional financing round of a company. They look for companies with outstanding technology addressing unmet needs in very large markets led by exceptional management. Once invested, Domain takes an active role in guiding the growth of the company. They take a seat on the Board of Directors in the vast majority of cases. Most of their investments are in private companies, but they also invest in small-cap public healthcare companies that are implementing a new corporate strategy.

Suppliers
H. Lee Moffitt Cancer Center and Research Institute, Inc. Hospitals & Patient Services | TAMPA, FL

Moffitt Cancer Center in Tampa, Florida, has made a lasting commitment to the prevention and cure of cancer, working tirelessly in the areas of patient care, research and education to advance one step further in fighting this disease. Alan F. List, M.D. President/CEO Translational Research As part of an elite group of National Cancer Institute (NCI) Comprehensive Cancer Centers, Moffitt focuses on the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. Tradition of Excellence Since our first patient admission in October 1986, Moffitt physicians, scientists and staff members have worked together to establish a tradition of excellence offered in an atmosphere characterized by kindness, caring and hope. Our future growth in clinical care and research rests firmly on this tradition and makes possible the changes ahead. Mission The mission of Moffitt Cancer Center is to contribute to the prevention and cure of cancer. Vision Our vision is "to be the leader in scientific discovery and translation into compassionate care, cures, and prevention of cancer for our community and the world." As we grow to fulfill our mission, we will continue to be distinguished by our compassionate and effective patient care. Institutional Values S cientific, educational, and patient care excellence U nity in pursuit of our mission C reativity C ompassion for our patients and their families E mployees, volunteers, and faculty are our most prized resources S tewardship S ocial responsibility and ethics of the highest standard Moffitt Facts Moffitt Cancer Center is a not-for-profit institution. It includes private patient rooms, the Southeast’s largest Blood and Marrow Transplant Program, outpatient treatment programs that record more than 328,300 visits a year, the Moffitt Research Center, Moffitt Cancer Center at International Plaza, and Moffitt Cancer Center Screening and Prevention. In 2003, Moffitt opened its doors to the Muriel Rothman Building (Clinic) and Vincent A. Stabile Research Building. These two buildings dramatically increased the existing research and outpatient clinical space to better serve our patients.

Cognate BioServices, Inc. Pharmaceuticals | Hanover, MD

Cognate BioServices, Inc. engages in the provision of a broad range of commercialization services to regenerative medicine and advance cell therapy companies, organizations and institutions. The firm also provides specialized custom services to companies across all points of clinical and commercial development. Its services is consist of current good manufacturing practice (cGMP) manufacturing, process development, cell therapy services, and regulatory services. The company was founded in 2002 and is headquartered in Hanover, MD.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Biogen, Inc. Biotechnology - San Diego, CA

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Atara Biotherapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Atara Biotherapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Atara Biotherapeutics, Inc..